Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
The effects of desferrioxamine administration of aluminium kinetics during haemodialysis were studied. Desferrioxamine leads to an increase of plasma aluminium levels in patients on chronic haemodialysis which could be attributed to mobilisation of tissue aluminium. Furthermore the ultrafiltrable function of plasma aluminium was greatly enhanced thus increasing the effective concentration gradient of aluminium between plasma and dialysate. Desferrioxamine therefore leads to increased aluminium removal during haemodialysis and should be considered in the therapy of aluminium toxicity syndromes.
D000535:Aluminum / Q000097:blood*; D003676:Deferoxamine / Q000494:pharmacology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D007700:Kinetics; D006435:Renal Dialysis
D000535:Aluminum; D003676:Deferoxamine